Research Paper Volume 15, Issue 15 pp 7616—7636
An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer
Figure 8. Drug sensitivity analysis of patients with breast cancer in low-risk group and high-risk group. The distribution of IC50 values shows a significant difference between patients in the low-group and high-risk group among (A) AKT inhibitor VIII, (B) imatinib, (C) linsitinib, (D) paclitaxel, (E) phenformin, and (F) pyrimethamine. (G–L) Correlation analysis of risk score and drug sensitivity.